Cellectis S.A. (CLLS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cellectis S.A. (CLLS) Healthcare & Pipeline Overview

Cellectis S.A. specializes in immuno-oncology therapies utilizing gene-edited T-cells to effectively target and eliminate cancer cells, with a robust pipeline of allogeneic product candidates designed to address various hematologic malignancies.

What Is the Investment Thesis for CLLS?

Cellectis S.A. is positioned for growth within the biotechnology sector, driven by its advanced pipeline of gene-edited T-cell therapies aimed at treating various hematologic malignancies. The company's lead product candidate, UCART19, is in clinical trials and has the potential to capture a significant share of the $5 billion market for CAR T-cell therapies. Additionally, Cellectis's strategic partnerships with leading organizations in the healthcare sector enhance its research capabilities and market reach. The company faces risks, including regulatory hurdles and competition from established players in the immuno-oncology space. However, its innovative technology platform and strong pipeline provide a solid foundation for future growth, with several key clinical milestones expected in the next 12-24 months.

Based on FMP financials and quantitative analysis

CLLS Key Highlights

Market Cap of $314M reflects significant investment in innovative cancer therapies.

• Profit Margin of -98.7% indicates substantial R&D expenditures typical for clinical-stage biotech firms.
• Gross Margin of 78.9% showcases the potential for high profitability upon commercialization of therapies.
• Beta of 2.93 suggests high volatility, characteristic of biotech stocks influenced by clinical trial outcomes.
• No dividend yield as the company reinvests in R&D to advance its product pipeline.

Who Are CLLS's Competitors?

CLLS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CLLS's Key Strengths?

Innovative gene-editing technology that enhances T-cell therapy efficacy.

• Robust pipeline of allogeneic T-cell product candidates.
• Strong strategic partnerships that bolster research and development.

What Are CLLS's Weaknesses?

High burn rate typical of clinical-stage biotech companies.

• Dependence on successful clinical trial outcomes for future growth.
• Limited revenue generation until products are commercialized.

What Could Drive CLLS Stock Higher?

Results from ongoing clinical trials for UCART19 expected in Q3 2026.

• Strategic partnerships with leading biotech firms enhancing research capabilities.
• Regulatory submissions for UCART19 anticipated in late 2026.

What Are the Key Risks for CLLS?

Financial-distress signal — its Altman Z-Score of -1.25 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-80.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles that may delay product approvals.
• High competition from established players in the immuno-oncology space.
• Market volatility affecting funding and investment opportunities.

What Are the Growth Opportunities for CLLS?

• Expansion of UCART19: Cellectis's lead product candidate, UCART19, targets CD19-expressing hematologic malignancies and is currently in clinical trials. The global market for CAR T-cell therapies is expected to grow significantly, reaching $5 billion by 2027, providing a substantial opportunity for Cellectis to capture market share as clinical results progress.
• Development of ALLO-501 and ALLO-501A: These candidates are designed for relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. With the increasing incidence of these cancers, the market for effective treatments is expanding, and successful clinical trials could lead to rapid market entry and revenue generation.
• Strategic Alliances: Cellectis has formed partnerships with leading organizations, including Allogene Therapeutics and the University of Texas M.D. Anderson Cancer Center. These collaborations enhance research capabilities and facilitate access to broader markets, potentially accelerating the development and commercialization of its therapies.
• Emerging Therapies for Multiple Myeloma: The company is also developing UCARTCS1 and ALLO-715 for multiple myeloma, a cancer with a growing patient population. The increasing demand for effective treatments in this area presents a significant growth opportunity for Cellectis as it advances its pipeline.
• Regulatory Approvals: As Cellectis progresses through clinical trials, successful regulatory approvals from the FDA and EMA could lead to commercialization of its therapies. This would not only validate its technology but also open up new revenue streams in the lucrative oncology market.

What Are CLLS's Competitive Advantages?

• Proprietary gene-editing technology that enhances the efficacy of T-cell therapies.
• Strong pipeline of product candidates addressing unmet medical needs in oncology.
• Established strategic alliances with leading biotech firms and research institutions.

What Does CLLS Do?

Founded in 1999 and headquartered in Paris, France, Cellectis S.A. is a pioneering clinical-stage biotechnology company dedicated to advancing immuno-oncology therapies through innovative gene-editing technologies. The company develops allogeneic T-cell products that express chimeric antigen receptors (CARs), enabling them to specifically target and eradicate cancer cells. Cellectis operates primarily through two segments: Therapeutics and Plants, with a strong emphasis on its Therapeutics segment, which houses its promising pipeline of product candidates. Key developments include UCART19, aimed at treating CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia, and other candidates like ALLO-501 and ALLO-501A for relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. The company also has promising candidates like ALLO-316 for renal cell carcinoma and UCART123 for acute myeloid leukemia. Cellectis has established strategic alliances with notable organizations, including Allogene Therapeutics, Les Laboratoires Servier, and the University of Texas M.D. Anderson Cancer Center, enhancing its research and development capabilities. With a dedicated workforce of 216 employees, Cellectis is positioned to make significant contributions to the field of oncology through its innovative approaches and strategic collaborations.

What Products and Services Does CLLS Offer?

• Develops immuno-oncology therapies using gene-edited T-cells.
• Focuses on creating allogeneic T-cell product candidates for various cancers.
• Targets hematologic malignancies such as leukemia and lymphoma.
• Operates through Therapeutics and Plants segments.
• Engages in strategic alliances with leading biotech and research institutions.
• Conducts clinical trials to advance its product pipeline.

How Does CLLS Make Money?

• Generates revenue through the commercialization of innovative cancer therapies.
• Engages in strategic partnerships to enhance research and development capabilities.
• Invests heavily in R&D to advance its product pipeline and achieve regulatory approvals.
• Explores licensing agreements for its technology and product candidates.

What Industry Does CLLS Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in gene editing and immunotherapy. The global CAR T-cell therapy market is projected to reach $5 billion by 2027, reflecting increasing investment in innovative cancer treatments. Cellectis S.A. operates in a competitive landscape, facing rivals such as Novartis and Gilead Sciences, which also develop CAR T-cell therapies. The company's focus on allogeneic T-cell products differentiates it from competitors primarily focused on autologous therapies, positioning Cellectis as a potential leader in this emerging market.

Who Are CLLS's Key Customers?

• Healthcare providers and hospitals seeking innovative cancer treatments.
• Patients with specific hematologic malignancies.
• Research institutions collaborating on clinical trials and product development.

Company Profile

Cellectis S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO Andre Choulika. CLLS has traded publicly since 2015.

Return on equity for Cellectis S.A. stands at -80.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -19.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.52 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.8%, the inverse of the P/E and a quick read on earnings relative to price.

CLLS Valuation & Market Position

With a $314M market cap, Cellectis S.A. sits in the small-cap segment of the market. Analyst price targets span from $9.00 to $9.00, with a consensus of $9.00. At the current price of $3.13, that implies approximately 188% upside potential. Relative to its peer group, CLLS's quantitative score of 14/100 is below the peer average of 73/100.

Quarterly Financial Performance: Cellectis S.A.

Revenue for Cellectis S.A. came in at $5.2M during Q2 FY2026, a 9.9% contraction versus the preceding quarter. The company recorded a net loss of $21.8M, with diluted EPS of $-0.22. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, CLLS averaged $-0.16 in diluted EPS.

Cellectis S.A.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.25 places it in the distress zone, a signal of elevated financial risk.

Cellectis S.A. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 48.5% below estimates on average.

CLLS Financials

CLLS Latest News

CLLS Analyst Consensus

CLLS MoonshotScore

CLLS Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources